Statements & Guidelines



As Enteryx is already an FDA-approved and coded product, SAGES has
no objection to Boston Scientifics' request to initiate training
programmes, as per their protocol, and to promote and market Enteryx
in South Africa.

There is no specific code at present for this
procedure, but there are other coding structures available for use
by trained and approved interventionists. Those completing their
Enteryx training will have their names made available to the medical

  • The role of endoluminal therapies in the management of patients with GORD has been debated in the editorial pages of prominent journals and at national meetings. Many physicians have called for larger studies with longer follow-up and randomised - controlled designs before proceeding with clinical use of these therapies. Physicians have embraced a particular therapy and use it clinically in interested patients. We clearly need well-controlled long-term efficacy studies for these techniques and funding for such ambitious and expensive products is becoming increasingly difficult. Anecdotally, some patients respond extremely well to these therapies, while others are not improved at all. 

  • Endoluminal therapies may fit into the clinical management of patients in several ways. Their ultimate clinical role will depend on their success rate and durability of the response. They may be used as primary therapy, reserving laparoscopic fundoplication for those patients that fail endoluminal therapy. They may also have a role in the treatment of patients who fail laparoscopic fundoplication. 

  • Where are we headed? Endoluminal therapies are expected to improve with long-lasting rapid and even safer procedures available for patients with GORD. Whether it is one of the currently available technologies or a totally new modality, endoluminal therapies for GORD will continue to develop.


    He compares the various endoscopic techniques that are currently marketed or been introduced as novel therapies for GORD. 

    Radio frequency Energy Delivery (STRETTA) is the technique under consideration. Developed by Curon Medical Inc, Sunnyvale, CA. In South Africa the introduction, marketing and development is being managed by Perry-Hill International. 


    Endoscopic therapies should be considered for patients who respond in part to PPI, but do not wish to take long-term medication. In addition, possible candidates are patients who respond partly to PPI, but do not want surgery, patients who are afraid of possible long-term effects of PPI therapy, patients with regurgitation not responsive to PPI and who are “not yet ready for surgery”, patients intolerant to PPI and possibly patients who have failed fundoplication for GORD. 

    The best candidates for endoscopic therapies are those who have well established GORD documented by endoscopy or pH-monitoring and oesophageal motility studies and have responded to PPI. Other potential candidates are those with PPI-responsive GORD despite normal twenty four hour pH study (non-erosive reflux disease - NERD). Consideration should also be given to patients with PPI-responsive extra-oesophageal manifestations of reflux. The endoscopic procedures currently available are not appropriate for the late complications of oesophageal shortening or stricture, poor oesophageal function and dysphagia.